Effects of bezafibrate in patients with chronic hepatitis C virus infection: Combination with interferon and ribavirin

Journal of Viral Hepatitis

Volumn 13, Issue 7, 2006, Pages 441-448

  Fujita, N ^a,b   Kaito, M ^a   Kai, M ^b   Sugimoto, R ^a   Tanaka, H ^a   Horiike, S ^a   Konishi, M ^c   Iwasa, M ^a   Watanabe, S ^c   Adachi, Y ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b National Hospital Organization Mie Chuo Medical Center   (Japan)

^c MIE UNIVERSITY   (Japan)

Author keywords

Fibrate; Immunoprecipitation; Peroxisome proliferator activated receptor ; Real time detection PCR; Ultracentrifugation

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BEZAFIBRATE; LIPID; LOW DENSITY LIPOPROTEIN; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; HYPERLIPIDEMIA; IMMUNOPRECIPITATION; LIPID BLOOD LEVEL; LIVER DYSFUNCTION; MALE; PILOT STUDY; PRIORITY JOURNAL; SUCROSE DENSITY GRADIENT CENTRIFUGATION;

ADULT; AGED; ANTILIPEMIC AGENTS; ANTIVIRAL AGENTS; BEZAFIBRATE; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; HYPERLIPIDEMIAS; INTERFERONS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; VIREMIA;

EID: 33745193547     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2005.00718.x     Document Type: Article

References (30)

1. WHO Viral Hepatitis Prevention Board. Global surveillance and control of HCV. J Viral Hepat 1999 6: 35 48.
2. Di Bisceglie AM. Natural history of hepatitis C: its impact on clinical management. Hepatology 2000 31: 1014 1018.
3. Wong JB Poynard T Ling MH et al. Cost-effectiveness of 24 or 48 weeks of interferon-α2b alone or with ribavirin as initial treatment of chronic hepatitis C. Am J Gastroenterol 2000 95: 1524 1530.
4. Manns MP McHutchison G Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358: 958 965.
5. Fried MW Shiffman ML Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347: 975 982.
6. Bradley D McCaustland K Krawczynski K et al. Hepatitis C virus: buoyant density of the factor VIII-derived isolate in sucrose. J Med Virol 1991 34: 206 208.
7. Kaito M Watanabe S Tsukiyama-Kohara K et al. Hepatitis C virus particle detected by immunoelectron microscopic study. J Gen Virol 1994 75: 1755 1760.
8. Ishida S Kaito M Kohara M et al. Hepatitis C virus core particle detected by immunoelectron microscopy and optical rotation technique. Hepatol Res 2001 20: 335 347.
9. Maillard P Krawcznski K Nitkiewicz J et al. Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients. J Virol 2001 75: 8240 8250.
10. Hijikata M Shimizu YK Kato H et al. Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. J Virol 1993 67: 1953 1958.
11. Choo SH So HS Cho JM et al. Association of hepatitis C virus particles with immunoglobulin: a mechanism for persistent infection. J Gen Virol 1995 76: 2337 2341.
12. Thomssen R Bonk S Propfee C et al. Association of hepatitis C virus in human sera with beta-lipoprotein. Med Microbiol Immunol 1992 181: 293 300.
13. Manzini P Dusheiko GM Brown DJC et al. Hepatitis C virus (HCV) tends to associate preferentially with high-density lipoproteins by standard ultracentrifugal fractionation of plasma from patients with chronic HCV infection. Hepatol Res 1998 11: 158 165.
14. Andre P Komurian-Pradel F Deforges S et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 2002 76: 6919 6928.
15. Agnello V Abel G Elfahal M et al. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999 96: 14766 14771.
16. Monazahian M Bohme I Bonk S et al. Low density lipiprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol 1999 57: 223 229.
17. Schettler V Monazahian M Wieland E et al. Effect of heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) apheresis on hepatitis C plasma virus load. Ther Apher 2001 5: 384 386.
18. Takeuchi T Katsume A Tanaka T et al. Real-time detection system for quantification of hepatitis C virus genome. Gastroenterology 1999 116: 636 642.
19. Okamoto H Sugiyama Y Okada S et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992 73: 673 679.
20. Fujita N Kaito M Ishida S et al. Paraformaldehyde protects of hepatitis C virus particles during ultracentrifugation. J Med Virol 2001 63: 108 116.
21. Thomssen R Bonk S Thiele A. Density heterogeneities of hepatitis C virus in human sera due to the binding of beta-lipoproteins and immunoglobulins. Med Microbiol Immunol 1993 182: 329 334.
22. Prince AM Huima-Byron T Parker TS et al. Visualization of hepatitis C virions and putative defective interfering particles isolated from low-density lipoproteins. J Viral Hepat 1995 3: 11 17.
23. Krey G Raissant O Horset FL et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator dependent receptor ligand assay. Mol Endocrinol 1997 11: 779 791.
24. Peterhans E. Oxidants and antioxidants in viral diseases: disease mechanisms and metabolic regulation. J Nutr 1997 127: 962 965.
25. Prosch S Staak K Stein J et al. Stimulation of the human cytomegalovirus IE enhancer/promoter in HL-60 cells by TNFα is mediated via induction of NF-κB. Virology 1995 208: 197 206.
26. Tanaka N Sanda T Okamoto H et al. RelA-associated inhibitor blocks transcription of human immunodeficiency virus type 1 by inhibiting NF-κB and Sp 1 actions. J Virol 2002 76: 8019 8030.
27. Su AI Pezacki JP Wodicka L et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci USA 2002 99: 15669 15674.
28. Kobayashi Y Watanabe S Konishi M et al. Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-beta. Hepatology 1993 18: 1319 1325.
29. Min AD Jones JF Esposito S et al. Efficacy of high-dose interfron in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone. Am J Gastroentrol 2001 96: 1143 1149.
30. Shiffman ML. Retreatment of patients with chronic hepatitis C. Hepatology 2002 36 ( Suppl. 1 128 134.